DEA Warns of Extortion Scam Targeting Healthcare Providers
The DEA has issued a warning concerning an extortion scam involving calls from someone purporting to be a DEA agent attempting to extort money.
All articles by Steve Duffy
US Cuts Deal With Pfizer, BioNTech for 100 Million COVID-19 Vaccine Doses
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the Food and Drug Administration.
Validation Study Data Released for Some COVID-19 Antibody Tests
The analysis included results from 2 tests that have received EUA: the SARS-CoV-2 ELISA test (Euroimmun) and the COVID-19 IgG/IgM Rapid Test Cassette (Healgen).
Haymarket Medical Network Joins Ad Council Private Marketplace
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
Ultomiris to Be Evaluated for Severe COVID-19 in Phase 3 Trial
Study will enroll approximately 270 adult patients globally.
ABIM Relaxes MOC Requirements Due to COVID-19
The American Board of Internal Medicine (ABIM) announced that certified physicians who have a Maintenance of Certification (MOC) requirement due in 2020 will now have until the end of 2021 to complete it.
Avatrombopag Designated Orphan Drug for Chemo-Induced Thrombocytopenia
The FDA has granted Orphan Drug designation to avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia, a complication that may lead to chemotherapy dose delays and regimen changes.
Haymarket Medical Education Receives Interprofessional Joint Accreditation for the Healthcare Team
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
FDA Greenlights New Rituxan Biosimilar
The Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan (Genentech and Biogen), for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangitis and microscopic polyangiitis. The approval was based on a comprehensive data package which included results from the REFLECTIONS B3281006 study in…
Rivaroxaban May Be Safe, Effective for Pediatric VTE Treatment, Says Study
Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.
-
Loading...
-
Loading...
Next post in Thrombotic Disorders
